MiMedx Group Inc (MDXG)
6.43
-0.08
(-1.23%)
USD |
NASDAQ |
Apr 24, 16:00
6.45
+0.02
(+0.31%)
After-Hours: 20:00
MiMedx Group Revenue (Annual): 321.48M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 321.48M |
| December 31, 2022 | 267.84M |
| December 31, 2021 | 242.02M |
| December 31, 2020 | 248.23M |
| December 31, 2019 | 299.26M |
| December 31, 2018 | 359.11M |
| December 31, 2017 | 321.14M |
| December 31, 2016 | 221.71M |
| Date | Value |
|---|---|
| December 31, 2015 | 187.30M |
| December 31, 2014 | 118.22M |
| December 31, 2013 | 59.18M |
| December 31, 2012 | 27.05M |
| December 31, 2011 | 7.760M |
| December 31, 2010 | 0.7889M |
| December 31, 2009 | 0.0008M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
242.02M
Minimum
2021
321.48M
Maximum
2023
275.77M
Average
267.84M
Median
2022
Revenue (Annual) Benchmarks
| TELA Bio Inc | 58.45M |
| Amylyx Pharmaceuticals Inc | 380.79M |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.202M |
| IGC Pharma Inc | 0.911M |